• In conclusion atorvastatin but not pravastatin

  2022-09-01

  

  In conclusion, atorvastatin but not pravastatin impaired glucose utilization in C2C12 cells and glucose tolerance in HFD mice, which may be partly due to the inhibition of GLUT4 translocation in muscle cells. The decrease in the cholesterol level induced by atorvastatin may partly account for the in

• br Acknowledgements br Introduction Protein translation dema

  2022-09-01

  

  Acknowledgements Introduction Protein translation demands high fidelity. There are number of molecular checkpoints to fulfill this demand. Among these, insuring that a particular tRNA gets aminoacylated by its conjugate amino acid, which in turn is catalyzed by a particular aminoacyl-tRNA synt

• The MeO CFO phen yl group was then selected for

  2022-09-01

  

  The 1-MeO-4-CFO-phen-2-yl group was then selected for the C-3 position when we investigated the aryl substituents at the C-6 position of indazole. As shown in , C-6 position seems to be more tolerant than the C-3 position, as all the aryl groups examined exhibited potent hGCGR activity. Interestingl

• The in vivo biological activity of the four

  2022-09-01

  

  The in vivo biological activity of the four novel analogues was then systematically assessed in three animal models including normal control, high fat fed and ob/ob mice. As expected from earlier in vitro studies, all four glucagon receptor antagonists had minor effects on glucose or insulin concent

• The effects of GHS R

  2022-09-01

  

  The effects of GHS-R1a blockade on alcohol-related outcomes have been examined in numerous preclinical experiments, utilizing various GHS-R1a antagonists (JMV 2959, [D-Lys3]-GHRP-6, BIM 28163) and rodent species (prairie vole, mouse, rat). In spite of methodological differences, the results consiste

• So far several methods have been used

  2022-09-01

  

  So far, several methods have been used to monitor the level of GJC and its regulation in astrocytes studied in acute Fructose Colorimetric/Fluorometric Assay Kit slices (see Giaume et al., 2012). This mainly includes approaches based either on electrophysiological properties of gap junction channels

• Clinical trials of all GSIs have ended prematurely raising t

  2022-09-01

  

  Clinical trials of all GSIs have ended prematurely, raising the question on our understanding of their target, the γ-secretase/presenilin. Development of compounds to target γ-secretase and reduce Aβ production is complicated by the fact that γ-secretase/presenilin has critical biological function,

• br The potential of EPA

  2022-09-01

  

  The potential of EPA-Ffar4 signaling as a novel intervention for HFpEF Conclusions and future directions Optimization of ω3-PUFA/EPA-therapy based upon titration to achieve therapeutic levels: A pressing clinical challenge is to continue to define the benefit of ω3-PUFA/EPA-therapy. Recent ana

• Barasertib Interestingly we have shown that OA required FFAR

  2022-09-01

  

  Interestingly, we have shown that OA required FFAR4 to induce osteoblast gene expression in MC3T3-E1 pre-osteoblasts, but not to inhibit osteoclastogenesis in RAW264.7 murine macrophages. As previously suggested, FFAR1 may mediate the effects of OA in osteoclasts. However, FFAR1 has also been shown

• The receptor binding assay used in

  2022-09-01

  

  The receptor binding assay used in our previous study demonstrated that propofol competitively binds to FPR1, thus blocking the downstream signal transduction of FPR1 and inhibiting neutrophil immune activities [8]. In this study, we assessed the pharmacological action of fMMYALF in the presence of

• Due to the presence of all FGFRs in the epithelium

  2022-09-01

  

  Due to the presence of all FGFRs in the epithelium, there are several FGFs ligands that could be binding to these FGF receptors, namely FGFs 1–4, 8–10, 16 and 18–20. By evaluating the known roles of FGFs in epithelial-mesenchymal interactions and in bone development, this list can be reduced. For ex

• Another lever to efficiently eradicate tumors including ovar

  2022-09-01

  

  Another lever to efficiently eradicate tumors including ovarian cancer might rely on their high addiction to iron [34]. In fact, ultrasmall silica-based nanoparticles, functionalized with melanoma-targeting peptide, efficiently triggered ferroptosis not only in cell culture but also in tumor bearing

• In this study according to the critical

  2022-09-01

  

  In this study, according to the critical pharmacophore T31, Y113 and R140 of FBPase, using the strategy of pharmacophore-based virtual screening, a series of novel scaffold inhibitor targeted the AMP binding site of FBPase were screened, their inhibitory activities against FBPase were further tested

• Andexanet alfa works as a decoy for the

  2022-09-01

  

  Andexanet alfa works as a decoy for the FXa inhibitor to bind to irreversibly. The recently completed ANDEXA-4 trial, which was a prospective, open-label, single group study, found that patients achieved good or excellent hemostasis in 82% of subjects [, , ]. There was an overall 10% thromboembolic

• Finally we investigated increasing basicity as a

  2022-08-30

  

  Finally, we investigated increasing basicity as a way to improve solubility. We expected that conversion of the ether linkage of to an -methyl group could improve solubility. More than expected, Parthenolide demonstrated significant improvement of values of solubility for the two media, especiall

8603 records 442/574 page Previous Next First page 上5页 441442443444445 下5页 Last page